José Bines

Impact of trastuzumab on Anti-Müllerian (AMH) levels in patients undergoing (neo) adjuvant treatment for breast cancer: a systematic review

Roberta Monteiro Batista Sarmento, José Roberto Lapa e Silva, Gustavo Arantes Rosa Maciel, Claudia Ferrer et autres

br (code pays fourni par la source)

Reoperation rates following breast-conserving surgery in a contemporary cohort

Anne Dominique Nascimento Lima, Eduardo Camargo Millen, Francisco Pimentel Cavalcante, Felipe Zerwes et autres

br (code pays fourni par la source)

Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA mutated triple negative breast cancer cohort

Monique Celeste Tavares, Flávia Cavalcanti Balint, R. B. Barroso-Sousa, Laura Testa Testa et autres

br, ar, us, uy (code pays fourni par la source)

Supplementary Figure S2 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Karama Asleh, Aňa Lluch, Angela Goytain, Carlos H. Barrios et autres

Supplementary Figure S4 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Karama Asleh, Aňa Lluch, Angela Goytain, Carlos H. Barrios et autres

Supplementary Tables S1-S10 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Karama Asleh, Aňa Lluch, Angela Goytain, Carlos H. Barrios et autres

Supplementary Figure S5 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Karama Asleh, Aňa Lluch, Angela Goytain, Carlos H. Barrios et autres

Supplementary Figure S3 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Karama Asleh, Aňa Lluch, Angela Goytain, Carlos H. Barrios et autres

Supplementary Figure S1 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Karama Asleh, Aňa Lluch, Angela Goytain, Carlos H. Barrios et autres

Supplementary Data S1-S2 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Karama Asleh, Aňa Lluch, Angela Goytain, Carlos H. Barrios et autres

Supplementary Table S8 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Federico Rojo, Clive R. Taylor, Carlos H. Barrios, Laura Torrecillas et autres

Supplementary Table S9 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Federico Rojo, Clive R. Taylor, Carlos H. Barrios, Laura Torrecillas et autres